Stem Point Capital LP Syndax Pharmaceuticals Inc Transaction History
Stem Point Capital LP
- $312 Billion
- Q2 2025
A detailed history of Stem Point Capital LP transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Stem Point Capital LP holds 2,372,634 shares of SNDX stock, worth $37.6 Million. This represents 7.13% of its overall portfolio holdings.
Number of Shares
2,372,634
Previous 1,598,594
48.42%
Holding current value
$37.6 Million
Previous $19.6 Billion
13.14%
% of portfolio
7.13%
Previous 6.26%
Shares
7 transactions
Others Institutions Holding SNDX
# of Institutions
248Shares Held
100MCall Options Held
1.28MPut Options Held
1.29M-
Kynam Capital Management, LP Princeton, NJ8.52MShares$135 Million9.53% of portfolio
-
Black Rock Inc. New York, NY7.91MShares$125 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY5.8MShares$91.8 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.03MShares$79.7 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.07MShares$64.4 Million3.84% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $896M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...